Investigative and Clinical Urology

  • 제59권6호
  • /
  • Pages.399-409
  • /
  • 2018
  • /
  • 2466-0493(pISSN)
  • /
  • 2466-054X(eISSN)
대한비뇨의학회 (The Korean Urological Association)
권호 표지
DOI QR코드

DOI QR Code

Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms

  • 투고 : 2018.09.23
  • 심사 : 2018.10.14
  • 발행 : 2018.11.10
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: To analyze data from an observational, prospective, cumulative registry study in 805 hypogonadal men stratified by mild or moderate-to-severe lower urinary tract symptoms (LUTS) according to International Prostate Symptom Score. Materials and Methods: A total of 412 men underwent testosterone therapy (TTh) with injectable testosterone undecanoate, 393 men served as untreated controls. Measures of urinary function, anthropometric and metabolic parameters were performed at least twice per year. Results: Data from 615 men with mild LUTS (253 treated, 362 untreated) and 190 with moderate-to-severe LUTS (159 treated, 31 untreated) were available. During a follow-up period of 8 years a significant improvement of LUTS was noted for all TTh-patients whereas the control-groups showed deterioration or fluctuation around initial values. Despite advancing age, TTh fully prevented worsening of symptoms. In parallel, a considerable improvement of anthropometric parameters, lipids and glycemic control, blood pressure, C-reactive protein, and quality of life was found. Moderate-to-severe LUTS was associated with worse cardiometabolic risk profile at baseline as well as worse cardiovascular outcomes during follow-up in comparison to mild LUTS. Effect size of TTh was more pronounced in men with moderate-to-severe than with mild LUTS. Conclusions: Correcting hypogonadism by TTh is highly effective and safe for improving LUTS in hypogonadal men. TTh may also improve cardiometabolic risk and major adverse cardiovascular events.

키워드

참고문헌

  1. Shigehara K, Namiki M. Late-onset hypogonadism syndrome and lower urinary tract symptoms. Korean J Urol 2011;52:657-63. https://doi.org/10.4111/kju.2011.52.10.657
  2. Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol 2014;30:170-6. https://doi.org/10.4103/0970-1591.126900
  3. Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rep 2010;5:212-8. https://doi.org/10.1007/s11884-010-0067-2
  4. Kalinchenko S, Vishnevskiy EL, Koval AN, Mskhalaya GJ, Saad F. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male 2008;11:57-61. https://doi.org/10.1080/13685530801953994
  5. Vignozzi L, Morelli A, Corona G, Sebastianelli A, Serni S, Gacci M, et al. Testosterone protects the lower urinary tract from metabolic syndrome-induced alterations. Horm Mol Biol Clin Investig 2012;11:329-37.
  6. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011;60:106-17. https://doi.org/10.1016/j.eururo.2011.03.055
  7. Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol 2016;13:108-19. https://doi.org/10.1038/nrurol.2015.301
  8. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012;61:560-70. https://doi.org/10.1016/j.eururo.2011.11.013
  9. De Nunzio C, Cindolo L, Gacci M, Pellegrini F, Carini M, Lombardo R, et al. Metabolic syndrome and lower urinary tract symptoms in patients with benign prostatic enlargement: a possible link to storage symptoms. Urology 2014;84:1181-7. https://doi.org/10.1016/j.urology.2014.07.018
  10. Cohen PG. Abdominal obesity and intra-abdominal pressure: a new paradigm for the pathogenesis of the hypogonadalobesity-BPH-LUTS connection. Horm Mol Biol Clin Investig 2012;11:317-20.
  11. Baas W, Kohler TS. Testosterone replacement therapy and voiding dysfunction. Transl Androl Urol 2016;5:890-7. https://doi.org/10.21037/tau.2016.08.11
  12. Haider KS, Haider A, Doros G, Traish A. Long-term testosterone therapy improves urinary and sexual function, and quality of life in men with hypogonadism: results from a propensity matched subgroup of a controlled registry study. J Urol 2018;199:257-65. https://doi.org/10.1016/j.juro.2017.07.039
  13. Wallis CJ, Lo K, Lee Y, Krakowsky Y, Garbens A, Satkunasivam R, et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes Endocrinol 2016;4:498-506. https://doi.org/10.1016/S2213-8587(16)00112-1
  14. Haider A, Zitzmann M, Doros G, Isbarn H, Hammerer P, Yassin A. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. J Urol 2015;193:80-6. https://doi.org/10.1016/j.juro.2014.06.071
  15. Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male 2011;14:53-8. https://doi.org/10.3109/13685538.2010.518178
  16. Ko YH, Moon du G, Moon KH. Testosterone replacement alone for testosterone deficiency syndrome improves moderate lower urinary tract symptoms: one year follow-up. World J Mens Health 2013;31:47-52. https://doi.org/10.5534/wjmh.2013.31.1.47
  17. Yucel C, Keskin MZ, Peskircioglu CL. The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Curr Urol 2017;11:4-8. https://doi.org/10.1159/000447187
  18. Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology 2014;83:167-73. https://doi.org/10.1016/j.urology.2013.08.019
  19. Debruyne FM, Behre HM, Roehrborn CG, Maggi M, Wu FC, Schroder FH, et al. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU Int 2017;119:216-24. https://doi.org/10.1111/bju.13578
  20. Kohn TP, Mata DA, Ramasamy R, Lipshultz LI. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur Urol 2016;69:1083-90. https://doi.org/10.1016/j.eururo.2016.01.043
  21. Kathrins M, Doersch K, Nimeh T, Canto A, Niederberger C, Seftel A. The relationship between testosterone-replacement therapy and lower urinary tract symptoms: a systematic review. Urology 2016;88:22-32. https://doi.org/10.1016/j.urology.2015.11.006
  22. Kupelian V, Chiu GR, Araujo AB, Williams RE, Clark RV, McKinlay JB. Association of sex hormones and C-reactive protein levels in men. Clin Endocrinol (Oxf) 2010;72:527-33. https://doi.org/10.1111/j.1365-2265.2009.03713.x
  23. Lin PH, Freedland SJ. Lifestyle and lower urinary tract symptoms: what is the correlation in men? Curr Opin Urol 2015;25:1-5. https://doi.org/10.1097/MOU.0000000000000121
  24. Yelsel K, Alma E, Eken A, Gulum M, Ercil H, Ayyildiz A. Effect of obesity on International Prostate Symptom Score and prostate volume. Urol Ann 2015;7:371-4.
  25. Saad F, Yassin A, Doros G, Haider A. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int J Obes (Lond) 2016;40:162-70. https://doi.org/10.1038/ijo.2015.139
  26. Gacci M, Corona G, Sebastianelli A, Serni S, De Nunzio C, Maggi M, et al. Male lower urinary tract symptoms and cardiovascular events: a systematic review and meta-analysis. Eur Urol 2016;70:788-96. https://doi.org/10.1016/j.eururo.2016.07.007
  27. Russo GI, Castelli T, Privitera S, Fragala E, Favilla V, Reale G, et al. Increase of Framingham cardiovascular disease risk score is associated with severity of lower urinary tract symptoms. BJU Int 2015;116:791-6. https://doi.org/10.1111/bju.13053

피인용 문헌

  1. The Optimal Indication for Testosterone Replacement Therapy in Late Onset Hypogonadism vol.8, pp.2, 2018, https://doi.org/10.3390/jcm8020209
  2. Metabolic Effects of Testosterone Replacement Therapy in Patients with Type 2 Diabetes Mellitus or Metabolic Syndrome: A Meta-Analysis vol.2020, pp.None, 2018, https://doi.org/10.1155/2020/4732021
  3. Efficacy and Safety of Testosterone Treatment in Men: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians vol.172, pp.2, 2018, https://doi.org/10.7326/m19-0830
  4. The association between metabolic syndrome and benign prostatic hyperplasia: a systematic review and meta-analysis vol.23, pp.5, 2018, https://doi.org/10.1080/13685538.2020.1771552
  5. The prevalence and associated factors of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging males vol.23, pp.5, 2018, https://doi.org/10.1080/13685538.2020.1781806
  6. Relationship between serum total testosterone and prostate volume in aging men vol.11, pp.1, 2018, https://doi.org/10.1038/s41598-021-93728-1